Latest news with #FrazierLifeSciences
Yahoo
31-07-2025
- Business
- Yahoo
Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
Frazier Life Sciences XII, L.P. will focus on creating and investing in pioneering companies developing novel therapeutics PALO ALTO, Calif., July 31, 2025--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong support from both longstanding and new limited partners. Consistent with prior FLS venture funds, FLS XII will primarily invest in company creation and early-stage private biopharmaceutical companies. "We appreciate the continued support of our limited partners, many of whom have been with us since the launch of our first dedicated venture fund in 2016," said Patrick Heron, Managing Partner at Frazier Life Sciences. "With FLS XII, we look forward to continuing to work with exceptional entrepreneurs to advance therapeutic programs with the potential to address significant medical needs." Frazier Life Sciences has raised over $3.6 billion across five dedicated venture funds since 2016, alongside more than $1.7 billion raised in long-only public funds since 2021. The FLS team includes seven investment partners and a growing group of over 35 investment professionals, operating professionals, and senior advisors with broad biopharmaceutical experience across therapeutic areas and company stages. The firm takes a hands-on, collaborative approach to company building, leading to 25 new companies launched since 2020. Noteworthy investments include Alpine Immune Sciences (acquired by Vertex), Arcutis Biotherapeutics (NASDAQ: ARQT), Mirum Pharmaceuticals (NASDAQ: MIRM), NewAmsterdam Pharma (NASDAQ: NAMS), Tarsus Pharmaceuticals (NASDAQ: TARS), and Amunix Pharmaceuticals (acquired by Sanofi), among others. About Frazier Life Sciences Frazier Life Sciences (FLS) invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Since 2016, the firm has raised over $5.3 billion including venture funds focusing on company creation and private companies and long-only public funds focused on small and mid-cap public companies. Since 2010, FLS portfolio companies have achieved over 65 FDA-approved therapeutics and completed more than 60 IPOs or strategic acquisitions. FLS is headquartered in Palo Alto, CA, with offices in San Diego, Seattle, and Boston. For more information, please visit and follow us on LinkedIn. View source version on Contacts For media inquiries, please contact: Ailsa Dalgliesh, of Investor Relations ailsa@
Business Wire
31-07-2025
- Business
- Business Wire
Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong support from both longstanding and new limited partners. Consistent with prior FLS venture funds, FLS XII will primarily invest in company creation and early-stage private biopharmaceutical companies. 'We appreciate the continued support of our limited partners, many of whom have been with us since the launch of our first dedicated venture fund in 2016,' said Patrick Heron, Managing Partner at Frazier Life Sciences. 'With FLS XII, we look forward to continuing to work with exceptional entrepreneurs to advance therapeutic programs with the potential to address significant medical needs.' Frazier Life Sciences has raised over $3.6 billion across five dedicated venture funds since 2016, alongside more than $1.7 billion raised in long-only public funds since 2021. The FLS team includes seven investment partners and a growing group of over 35 investment professionals, operating professionals, and senior advisors with broad biopharmaceutical experience across therapeutic areas and company stages. The firm takes a hands-on, collaborative approach to company building, leading to 25 new companies launched since 2020. Noteworthy investments include Alpine Immune Sciences (acquired by Vertex), Arcutis Biotherapeutics (NASDAQ: ARQT), Mirum Pharmaceuticals (NASDAQ: MIRM), NewAmsterdam Pharma (NASDAQ: NAMS), Tarsus Pharmaceuticals (NASDAQ: TARS), and Amunix Pharmaceuticals (acquired by Sanofi), among others. About Frazier Life Sciences Frazier Life Sciences (FLS) invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Since 2016, the firm has raised over $5.3 billion including venture funds focusing on company creation and private companies and long-only public funds focused on small and mid-cap public companies. Since 2010, FLS portfolio companies have achieved over 65 FDA-approved therapeutics and completed more than 60 IPOs or strategic acquisitions. FLS is headquartered in Palo Alto, CA, with offices in San Diego, Seattle, and Boston. For more information, please visit and follow us on LinkedIn.
Yahoo
05-06-2025
- Business
- Yahoo
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants proportionately to the amount of non-dilutive capital received, under certain circumstances Financing co-led by new investors Coastlands Capital and Frazier Life Sciences and included participation from Gilead Sciences, Inc., Logos Capital, Samsara BioCapital and other new and existing investors WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the closing of its previously announced underwritten public offering of pre-funded warrants and accompanying common stock warrants for initial gross proceeds of approximately $50.0 million before deducting underwriting discounts and commissions and offering expenses. In addition, if all of the Series B warrants and Series C warrants are exercised in cash at their exercise price of $0.75 per warrant, Xilio would receive up to $100.0 million of additional gross proceeds by the second half of 2026, for total gross proceeds of up to $150.0 million before deducting underwriting discounts and commissions and offering expenses. The financing was co-led by new investors Coastlands Capital and Frazier Life Sciences and included participation from Gilead Sciences, Inc., Logos Capital, Samsara BioCapital and other new and existing institutional investors. Overview of Pre-Funded Warrants and Common Stock Warrants In connection with the offering, Xilio issued pre-funded warrants to purchase 66,676,000 shares of common stock (the 'pre-funded warrants'), accompanied by Series A warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the 'Series A warrants'), Series B warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the 'Series B warrants') and Series C warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the 'Series C warrants'). The combined public offering price of one pre-funded warrant, one Series A warrant, one Series B warrant and one Series C warrant, which were sold together but are immediately separable, is $0.7499, which is equal to the combined offering price of the pre-funded warrants, Series A warrants, Series B warrants and Series C warrants, less the $0.0001 per share exercise price of the pre-funded warrants. The offering closed on June 5, 2025, and all of the warrants were sold by Xilio. The pre-funded warrants and Series A warrants may be exercised for cash or on a net exercise or 'cashless' basis, and the Series B warrants and Series C warrants may be exercised for cash or on a net exercise or 'cashless' basis provided there is no effective registration statement or prospectus available which covers the Series B warrants and Series C warrants and shares of common stock issuable upon exercise of the Series B warrants and Series C warrants. The Series B warrants are exercisable at an exercise price of $0.75 per share of common stock between November 1, 2025 and December 2, 2025, subject to the terms of the warrant. If all of the Series B warrants are exercised for cash at their exercise price, Xilio would receive up to $50.0 million in additional gross proceeds before the end of 2025. The Series C warrants are exercisable at an exercise price of $0.75 per share of common stock between June 1, 2026 and December 2, 2026, subject to the terms of the warrant. If all of the Series C warrants are exercised for cash at their exercise price, Xilio would receive up to $50.0 million in additional gross proceeds before the end of 2026. In addition, for each dollar of non-dilutive capital received by Xilio prior to the exercise or expiration of the Series B and Series C warrants, Xilio may elect to cancel a number of warrant shares equal to $1.00 divided by the $0.75 warrant exercise price (or one and one-third warrants) without any compensation paid by Xilio to the warrant holders. For example, if Xilio received $30.0 million in non-dilutive capital, it could elect to cancel 40.0 million of warrant shares. Xilio intends to use the net proceeds received from the offering to advance the development of its product candidates and for working capital requirements and other general corporate purposes. Leerink Partners acted as the sole bookrunner for the offering. A shelf registration statement on Form S-3 (File No. 333-285703), as amended, relating to the securities to be offered in the public offering was initially filed with the Securities and Exchange Commission (the 'SEC') on March 11, 2025, and declared effective on May 8, 2025. The offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A final prospectus supplement relating to the offering has been filed with the SEC and may be obtained for free by visiting the SEC's website at Copies of the preliminary prospectus supplement and final prospectus supplement relating to the offering may also be obtained by contacting Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@ This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the use of proceeds of the offering. The words 'aim,' 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'seek,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. These and other risks and uncertainties are described in greater detail in the sections entitled 'Risk Factor Summary' and 'Risk Factors' in Xilio's filings with the SEC, including Xilio's most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements. Investor and Media Contact Scott YoungVice President, Investor Relations and Corporate Communicationsinvestors@
Yahoo
27-05-2025
- Business
- Yahoo
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entered into a securities purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 20,790,120 shares ('Shares') of its common stock ('Common Stock') or, in lieu thereof, to certain investors, pre-funded warrants ('Pre-Funded Warrants') to purchase 6,963,556 shares of Common Stock, in a private placement. Each full Share (or Pre-Funded Warrant in lieu thereof) will be accompanied by a warrant (a 'Common Warrant') to purchase one-half of a share of Common Stock. The purchase price for each Share and accompanying Common Warrant will be $2.8825 (or $2.8824 for each Pre-Funded Warrant and accompanying Common Warrant). Lexeo anticipates the gross proceeds from the private placement to be approximately $80 million, before deducting any offering related expenses. The private placement is expected to close on May 28, 2025, subject to customary closing conditions. The Pre-Funded Warrants will have an exercise price of $0.0001 per share until exercised in full, and the Common Warrants will have an exercise price of $2.82 per share and expire on May 28, 2029. The private placement was co-led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors, including Adar1 Capital Management, Affinity Healthcare Fund, LP, Ally Bridge Group, Coastlands Capital, Surveyor Capital (a Citadel company), Vestal Point Capital, and Woodline Partners LP. 'This financing will enable Lexeo to build on its leadership in cardiac genetic medicines as we continue to advance our clinical stage pipeline,' said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. 'With the support of an exceptional group of new and existing long-term investors, we believe we remain well-positioned to accelerate development of our programs and drive innovation with next-generation therapies that could redefine the treatment paradigm for devastating cardiovascular conditions.' J.P. Morgan and Oppenheimer & Co. acted as co-lead placement agents for the transaction. Baird also acted as placement agent. Lexeo intends to use net proceeds from the private placement to fund advancement of ongoing clinical stage programs, and for working capital and general corporate purposes. The proceeds from this private placement, combined with current cash, cash equivalents and marketable securities are expected to fund Lexeo's operating and capital expenditures into 2028. The securities to be sold in this private placement have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or any state or other applicable jurisdiction's securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. Concurrently with the execution of the securities purchase agreement, Lexeo and the investors entered into a registration rights agreement pursuant to which the company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the 'SEC') registering the resale of the Shares and Common Stock underlying the Pre-Funded Warrants and Common Warrants(together, the 'Warrant Shares') sold in the private placement. Any offering of the Shares and Warrant Shares under the resale registration statement will only be made by means of a prospectus. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Company's securities, nor shall there be any offer, solicitation, or sale of the Company's securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the 'Minimum Price' requirement (as defined in the Nasdaq rules). About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, LX2020 for the treatment of plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others for devastating diseases with high unmet need. Cautionary Note Regarding Forward-Looking StatementsCertain statements in this press release may constitute 'forward-looking statements' within the meaning of the federal securities laws, including, but not limited to, statements regarding the expected closing of the private placement, anticipated receipt, impact and use of proceeds from the private placement, whether the conditions for the closing of the private placement will be satisfied, the filing of a registration statement or final prospectus, as applicable, to register the resale of the Shares and Warrant Shares to be issued and sold in the private placement, the anticipated cash runway following closing of the private placement , and other information that is not historical information. Words such as 'may,' 'might,' 'will,' 'objective,' 'intend,' 'should,' 'could,' 'can,' 'would,' 'expect,' 'believe,' 'design,' 'estimate,' 'predict,' 'potential,' 'develop,' 'plan' or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo's filings with the SEC), many of which are beyond the company's control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo's preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo's Annual Report on Form 10-K for the annual period ended December 31, 2024, filed with the SEC on March 24, 2025, Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 12, 2025, as amended, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Media Response:Media@ Investor Response:Carlo Tanzi, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-04-2025
- Business
- Yahoo
Frazier Life Sciences Appoints Aditya Kohli to Partner
PALO ALTO, Calif., April 17, 2025--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ: HLVX, IPO in 2022), Phathom Pharmaceuticals (NASDAQ: PHAT, IPO in 2019), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to see him step into this next chapter at the firm as Partner," said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. "With over 10 years of industry experience, Aditya will lend his leadership experience and extensive operating knowledge as we back and build the next generation of biotech companies." As Partner, Dr. Kohli will continue focusing on company creation while also expanding his role to include broader investment responsibilities and shaping FLS's investment strategy. "Frazier Life Sciences is an incredibly supportive team with a long-term mindset, which makes all the difference when it comes to making thoughtful investments and providing enduring support to our portfolio companies," said Dr. Kohli. "I'm excited to help lead our company creation efforts for innovative biotechs delivering novel therapeutics." Prior to joining FLS, Dr. Kohli was an Engagement Manager with McKinsey & Company. He earned his Ph.D. from the UC Berkeley and UC San Francisco joint graduate program in bioengineering and holds B.S. and degrees in biological engineering from the Massachusetts Institute of Technology (MIT). About Frazier Life Sciences Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including Venture Funds focusing on company creation and private companies and the long-only Public Funds focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals in biopharmaceuticals, primarily located in Palo Alto, Calif. (headquarters), San Diego, Seattle, Boston, New York, and London. For more information about Frazier Life Sciences, please visit and follow us on LinkedIn. View source version on Contacts For media inquiries, please contact: Ailsa Dalgliesh, of Investor Relations ailsa@ Sign in to access your portfolio
